Cell and gene therapy (CGT) manufacturing can be complex. Part of the process requires precise, contamination-free thawing across a variety of critical materials. While we often focus on thawing cryopreserved cell products, another key component in CGT workflows is the controlled thawing of viral vectors used in gene modification.
Researchers of King’s College London, UK, recently published their GMP workflow for gene-modified T-cell manufacturing, featuring the use of the Barkey plasmatherm for thawing retroviral vector aliquots stored at -80°C. The cell therapy GMP workflow and other details are presented in the paper, “Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells” published in the open access journal, Cells.
The ability to precisely thaw viral vectors, cell therapies, and other CGT materials in a Grade D (ISO) environment showcases the versatility and reliability of this dry thawing technology.
One Device, Multiple Thawing Applications
- Cryopreserved starting material (e.g. leukapheresis)
- Gene-modifying viral vectors (retroviral & lentiviral)
- QC and reference samples
- Final drug product preparation
Why GMP Manufacturers Choose Dry Thawing
- No contamination risks
- Thaws vials, bags, and bottles
- Compliant for cleanrooms and qualifiable
- Hands-free, consistent thawing
Discover the Barkey plasmatherm C&G for your cancer immunotherapy GMP workflow!